SCLX
NASDAQ · Pharmaceuticals
Scilex Holding Co
$7.52
-0.28 (-3.59%)
Financial Highlights (FY 2026)
Revenue
120.82M
Net Income
-155,437,743
Gross Margin
70.5%
Profit Margin
-128.7%
Rev Growth
+21.8%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 70.5% | 70.5% | 31.1% | 31.1% |
| Operating Margin | -147.4% | -132.6% | 21.5% | 26.8% |
| Profit Margin | -128.7% | -122.2% | 17.8% | 16.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 120.82M | 99.19M | 16.86M | 18.16M |
| Gross Profit | 85.19M | 69.94M | 5.24M | 5.64M |
| Operating Income | -178,045,932 | -131,561,033 | 3.63M | 4.87M |
| Net Income | -155,437,743 | -114,855,475 | 3.00M | 3.07M |
| Gross Margin | 70.5% | 70.5% | 31.1% | 31.1% |
| Operating Margin | -147.4% | -132.6% | 21.5% | 26.8% |
| Profit Margin | -128.7% | -122.2% | 17.8% | 16.9% |
| Rev Growth | +21.8% | +21.8% | +5.1% | -1.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 11.67M | 10.30M |
| Total Equity | — | — | 39.45M | 37.80M |
| D/E Ratio | — | — | 0.30 | 0.27 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -169,438,426 | -132,156,407 | 6.50M | 7.12M |
| Free Cash Flow | — | — | 2.15M | 2.89M |